Joel Greenblatt acquired 11 Thousand Intra-Cellular Therapies shares worth $1.45 Million. That's 0.01% of their equity portfolio (749th largest holding). The first Intra-Cellular Therapies trade was made in Q4 2016. Since then Joel Greenblatt bought shares three more times and sold shares on one occasions. The stake costed the investor $807 Thousand, netting the investor a gain of 80% so far.